Preclinical research published in Vaccines demonstrates Infectimune® significantly improved quantity and quality of potent multifunctional CD4 T cells compared to…
NAPLES, Fla., March 13, 2024 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK), a pioneering provider of healthcare…
BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: “PYXS”), a clinical stage company focused on developing next…
Company expects enrollment in Phase 1 proof-of-concept study of DNA-based vaccine technology to begin in Q2The application follows guidance provided…
International Society for Cell & Gene Therapy (ISCT) Names Dr. Lowdell with the Career Achievement Award in Cell and Gene Therapy…
Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024Preliminary data from ADVANCED-2…
Announced Positive Results from Second Cohort of Phase 1 Trial of Decoy20 Initiating Multi-Dosing for patients with solid tumors NEW…
Company to host conference call and webcast on Wednesday, March 27th at 8:30am EDT LYON, France, March 13, 2024 --…
ZYNLONTA® (loncastuximab tesirine-lpyl) net sales of $16.6 million in 4Q 2023 and $69.1 million for full year (FY) 2023; 4Q…
STAFFORD, Texas, March 13, 2024 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused…
